Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy
Jin Hyen Baek, Felice D’Agnillo, Florence Vallelian, Claudia P. Pereira, Matthew C. Williams, Yiping Jia, Dominik J. Schaer, Paul W. Buehler
Jin Hyen Baek, Felice D’Agnillo, Florence Vallelian, Claudia P. Pereira, Matthew C. Williams, Yiping Jia, Dominik J. Schaer, Paul W. Buehler
View: Text | PDF
Research Article

Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy

  • Text
  • PDF
Abstract

Massive transfusion of blood can lead to clinical complications, including multiorgan dysfunction and even death. Such severe clinical outcomes have been associated with longer red blood cell (rbc) storage times. Collectively referred to as the rbc storage lesion, rbc storage results in multiple biochemical changes that impact intracellular processes as well as membrane and cytoskeletal properties, resulting in cellular injury in vitro. However, how the rbc storage lesion triggers pathophysiology in vivo remains poorly defined. In this study, we developed a guinea pig transfusion model with blood stored under standard blood banking conditions for 2 (new), 21 (intermediate), or 28 days (old blood). Transfusion with old but not new blood led to intravascular hemolysis, acute hypertension, vascular injury, and kidney dysfunction associated with pathophysiology driven by hemoglobin (Hb). These adverse effects were dramatically attenuated when the high-affinity Hb scavenger haptoglobin (Hp) was administered at the time of transfusion with old blood. Pathologies observed after transfusion with old blood, together with the favorable response to Hp supplementation, allowed us to define the in vivo consequences of the rbc storage lesion as storage-related posttransfusion hemolysis producing Hb-driven pathophysiology. Hb sequestration by Hp might therefore be a therapeutic modality for enhancing transfusion safety in severely ill or massively transfused patients.

Authors

Jin Hyen Baek, Felice D’Agnillo, Florence Vallelian, Claudia P. Pereira, Matthew C. Williams, Yiping Jia, Dominik J. Schaer, Paul W. Buehler

×

Figure 6

Renal Hb exposure, metabolic activation, and oxidative stress.

Options: View larger image (or click on image) Download as PowerPoint
Renal Hb exposure, metabolic activation, and oxidative stress.
(A) Twent...
(A) Twenty-four–hour urine collections show hemoglobinuria in the old blood group. (B) Perls iron staining demonstrates regions of iron accumulation, shown as brown, and granular effect in the old blood and, to some extent, old blood plus Hp groups (original magnification, ×400). (C) Okajima’s staining for globin chain deposition after transfusions shows globin chain deposition as orange staining in the renal tubules (original magnification, ×400). (D) Tissue iron quantitation by the ferrozine method indicates a significant (P < 0.05) increase in total iron in kidneys after old blood transfusion compared with that after new blood transfusion. Iron after transfusion with new and old blood plus Hp did not differ from that in NTs. (E) Nrf-2 immunofluorescence at 24 hours after transfusion. Red immunofluorescence within Hoechst-stained blue nuclei indicates nuclear localization of Nrf-2 in old and to some extent old blood plus Hp. These observations were not observed in NTs or new blood–transfused animals kidneys (original magnification, ×600). (F) Nrf-2 nuclear Western blotting indicates a significant (P < 0.05) increase in nuclear Nrf-2 protein compared with that in NT, new blood, old blood plus Hp, and other transfusion groups. (G) HO-1 Western blotting indicates a significant increase in renal HO-1 after transfusion of old blood when compared with that of NTs and animals transfused with new blood and old blood plus Hp after 24 hours. Animals transfused with old blood plus Hp also demonstrated a significant increase (P < 0.05) in HO-1 relative to that in NTs and animals transfused with new blood. Scale bars (1 cm) = 25 μm (B and C); scale bars (6 mm) = 10 μm (E). *P < 0.05; #P < 0.05; †P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts